Acacia Pharma Raises $23.5 M Series B For Repurposing Drugs As Anti-Emetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Other product candidates in the cancer supportive care sector being developed by the U.K. virtual biotech include a liquid formulation of a muscarinic agonist for dry mouth and a megestrol/formoterol combination therapy for muscle wasting.